Dec-2016 to Present – Doral Medical Research, LLC
2000 to 2017 – The Community Research of South Florida
1999 to Present – Private Practice
1996 to 1999 – Internal Medicine Residency – ST. Vincent’s Hospital and Medical Center of New York
1996 – Nova -Southeast University School of Osteopathic Medicine – Doctor of Osteopathic Medicine
1991 – Florida International University, Master’ s Degree in Psychology
1988 – Florida International University, Bachelor’s Degree in Psychology
CERTIFICATION AND LICENSURE:
2010 – Board Certified Internal Medicine
1996 – Doctor of Osteopathic Medicine
1991 – Master’s Degree in Psychology
1988 – Bachelor‘s Degree in Psychology
Present Doral Medical Research, LLC
1999 to Present Private Practice
2002 to 2017 The Community Research of South Florida
1991 to 1992 – Miami Dade Community College – Department of Social Science Adjunct Professor of Psychology Wolfson Center Duties: Taught individual in Transition (PSY 1000) and introduction to Psychology (PSY2012)
1989-1990 – Florida International University – Dept. of Psychology, Professor’s Assistant Duties: Lectured Classes, graded test and Assignments, conducted office hours, prepared lectures and counseled students.
American College of Physicians
Dade-County Medical Association
American Medical Association
American Osteopathic Association
Palmetto General Hospital
Larkin Community Hospital
West Kendall Baptist Hospital
Memorial Hospital West
GCP Certification (CITI program)
Bristol Myers Squibb: A Phase III Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril.
Mylan Bertek Pharmaceuticals: A Phase III Double Blind Placebo-Controlled, Efficacy and safety of Nebivolol added to existing anti-hypertension treatment in patient s with Mild to Moderate Hypertension.
Ciba-Geigy: A Phase III Transicor (Beta-Blocker) Lopressor vs. Placebo, Lopressor vs. Hydrochlorothiazide, and Biopharm vs. Valsartan.
Bristol Myers Squibb: A Phase III Seventeen Cell, factorial trail. Multiple Dosages of the combination of Fosinipril.
Takeda (NCT01309828): Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants with Hypertension and Kidney Disease.
Takeda (NCT00591266): A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Coadministered With Amlodipine 5 mg in Subjects With Essential Hypertension
Daiichi Sankyo: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Co-Administration of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects with Hypertension.
Bristol Myers Squibb: Double-Blind Oral Amoxicillin/Clavulanate in the treatment of complicated skin and skin structure infection.
Regeneron Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multiple Dose Study of the Efficacy Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered XXXXX in Adolescents and Adults with Moderate to Severe Extrinsic Atopic Dermatitis.
Regeneron Pharmaceuticals: A Randomized Double-Blind, Placebo-Controlled to asses to safety and efficacy of an investigational cream product XXXXXX in Subjects with Moderate Plaque Psoriasis.
Regeneron Pharmaceuticals: Double-Blind Placebo Multiple Dose Study of the efficacy, Safety, and Tolerability of HUMIRA XXXX in Adults with Moderate to Severe Psoriasis.
Perdue Pharma: A Phase III Moderate to severe study on subjects with Osteoarthritis of the Knee.
DOV Pharmaceutical: A Phase III Moderate to severe study on subjects with osteoarthritis of back or shoulder.
GSK – OA of the Knee or Hip: An efficacy and safety study of sustained release paracetamol in subjects with OA.
CRI-Organon: A Phase III Open label safety and efficacy of Desogestrol containing oral contraceptive.
Galen Pharmaceutical: A Phase III double Blind Placebo Control to Determine the efficacy in relief of hot flushes in women receiving low dose oral estradiol acetate tablets.
Boehringer Ingelheim: A Phase III randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of Bl XXXX (10 mg and 25mg administered orally once daily) during 52 weeks in patients with type 3 diabetes mellitus and insufficient glycemic controlled on MDI insulin alone or with metformin.
Boehringer Ingelheim: A Phase III, Multicenter, international, randomized parallel group, double-blind cardiovascular safety study of BI 10773 (10mg and 25mg) administered orally once daily compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.
Bristol Myers Squibb: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to evaluate the safety and efficacy of XXXXXXX in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACE!) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive Medication.
Bristol Myers Squibb: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the safety and efficacy of XXXXXXX in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACE!) or Angiotensin Receptor Blocker (ARB).
GSK: -Monotherapy in combination with insulin
Takeda: A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter study to Determine the efficacy and Safety of 25 mg and 50 mg of TAK XXX in Combination with XXXX 100mg in Subjects with type 2 Diabetes Mellitus.
Astra Zeneca: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXXXX in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) NCT0 l 137474
AstraZeneca: A Study of XXXXX (XXXXX) in Patients with Type 2 Diabetes with Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication. NCT0 1195662
Astra Zeneca: A 24 weeks, Multicenter, randomized, double-blind age-stratified, placebo-controlled, phase III study with a 28 –week extension period to evaluate the efficacy and Safety of XXXX 10mg once daily in patients with type 2 diabetes, Cardiovascular disease, and hypertension, who exhibit inadequate glycemic Control on usual care.
Bayer Pharmaceuticals: A Randomized, Double-blind, placebo-controlled, Parallel-Group, Multicenter event-driven, Phase III study to investigate cardiovascular morbidity and mortality in subjects with type 2 Diabetes Mellitus, and the Clinical Diagnosis of Diabetic Kidney Disease.
Glaxo-Smith Kline: A Randomized, Double-blind, Double-dummy, placebo-controlled multicenter study to evaluate the efficacy and safety of XXXXXX inhalation powder and XXXXXX inhalation powder in the treatment of asthma in adult s and adolescents not currently treated with inhaled corticosteroids.
Glaxo-Smith Kline: A Randomized, Double-blind, multi-center study to evaluate the efficacy and safety of inhaled XXXXX in the treatment of persistent asthma in adults and adolescents currently, receiving mid to high strength inhaled corticosteroids.
GSK: A Clinical Outcomes Study to Compare the Effect of Fluticasone XXXXX/XXXXX Inhalation Powder 100/ 25mcg With Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease. NCT0 1313676
Sanz Pharmaceutical: Phase III XXXXX inhaler in subjects with COPD.
Paragon/ Abbott Pharmaceutical: A Phase III Study of the Efficacy of XXXXX 1200 mg BID, Controlled Release (CR), and 600 mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
Paragon/Abbott Pharmaceutical: Zileuton – Double-blind, Placebo Control to Evaluate Efficacy and Safety study in subjects with Asthma.
GSK: A 6-month safety and benefits study of inhaled fluticasone propionate /salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma. NCT01462344
Beckitt Benckiser/PPD: Double-Blind Randomized, Placebo-Controlled Study of XXXX for the treatment of symptom s of infection when two 600mg tablets are given every 12 hrs.
Biota: A Phase 2 Multicenter, randomized. Double-Blind, Placebo-Controlled Study of BTA 798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection.
Daiichi Sankyo – Fibromyalgia: A Randomized-Double-blind, Placebo and Active-controlled study of XXXXX in subjects with Pain Associated with Fibromyalgia.
Daiichi Sankyo – Fibromyalgia: An Open-Label extension study of DS-55 65 for 52-week in Pain Associated with Fibromyalgia.
Vertex – Uncomplicated Seasonal Influenza: A Phase 2b, Randomized, Double-blind, Placebo-Controlled, Parallel-group multicenter study of XXXXXX administered as Monotherapy and in combination with Oseltamivir for the treatment of Acute Uncom plicated Seasonal Influenza in Adults Subjects.
Perrigo – Herpes Simplex Labials: A Multi-Center Double-blind, Randomized Vehicle-Controlled, Parallel-Group, study to compare XXXX cream, 5% with Zovirax cream 5% and both active treatment to a vehicle control in treatment of recurrent herpes labial is.
Star Pharmaceutical: Bacterial Vaginosis. A Phase 3, Double, multicenter, randomized, placebo-controlled study to determine the efficacy and safety of XXXX Gel to prevent the recurrence of Bacterial Vaginosis.
Ferring: IBS (Constipation): A Multicenter, Open-label, Safety and tolerability extension trial of 5 mg and 10 mg Elobixibat daily in the treatment of Chronic Idiopathic Constipation.
Takeda – Obesity: A Randomized Double –Blinded, Placebo-and Active Controlled CNS Stimulants Study of: XXXX in Obese Subjects.
Zafgen – Obesity: A Randomized, Double-Blind, Placebo-controlled, parallel-group, multicenter, even-driven Phase Ill study to investigate the efficacy and safety of CNS stimulants, anorexiants on Obese subjects.
Ortho-McNeil Pharmaceutical: Acetaminophen w. codeine and placebo control.
Bristol Myers Squibb: Cholesterol, XXXXX Pheno Type II.
Pfizer: XXXXX (anti-Depressant)
Perdue Pharmaceutical: Chronic Moderate to Severe Migraine Opioid vs. placebo for pain management.
XBiotech USA, Inc: A Phase II, Open-Label , Dose Escalation Study of MABp 1 in Patients with Moderate to Severe Hidradenitis Suppurativa
XBiotech USA Inc: A Phase II, Open-Label , Dose Escalation Study of Bermekimab (MABp l) in Patients with Moderate to Severe Atopic Dermatitis
Yiling Pharmaceutical, Inc: A Multi-Center, Randomized, Double-Blind, And Placebo-Controlled Phase II Clinical Study To Investigate The Safety And Efficacy Of Two Doses Of KT07 Compared To Placebo In Subjects With Acute Uncomplicated Influenza
Bayer Pharmaceuticals: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of XXXXX in subjects with uterine fibroids. 2018
Bayer Pharmaceuticals: An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of XXXXX in subjects with uterine fibroids versus standard of care. 2017 NCT03194646
Merck Sharp & Dohme Corp: A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK- 7264 in Women with Moderate to Severe Endometriosis-related Pain.
Janssen Pharmaceuticals: A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a/2b Study to Evaluate Safety, Reactogenicity, Regimen Selection, Immunogenicity and Efficacy of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVAvectored HPV16/ 18 Vaccine Component in Otherwise Healthy Women with Persistent HPV 16 or 18 Infection of the Cervix.
Published a thesis for my master ‘s dissertation entitled ” The Relationship of knowledge of drug testing and personality characteristics to attitudes towards drug testing in the workplace “Published for Florida International University Poster.
Presentation at the American College of Physicians involving Chronic Obstructive Pulmonary Disease and Bronchodilators.